For patients with stage IA non-small cell lung cancer (NSCLC), lung resections, including lobectomy and segmentectomy, are ...

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...

New research highlights the promise of a novel stem cell treatment strategy for leptomeningeal brain metastasis (LBM), a ...

Lung-sparing surgery could enhance outcomes for early-stage lung cancer patients by preserving lung function while ...

Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel condensate-modulating mechanism of ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

For early-stage NSCLC, lobar resection has been the gold standard since 1995 with publication of the LCSG trial. Given that ...

Nov. 6, 2024 — Exhaled breath contains chemical clues to what's going on inside the body, including diseases like ... New, Rare Type of Small Cell Lung Cancer Identified Sep. 11, 2024 ...

New research presented at the 2025 Society of Thoracic Surgeons (STS) Annual Meeting reveals that anatomic lung resections, such as lobectomy and segmentectomy, are associated with improved long-term ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

metastatic disease), fewer than 10% will survive longer than 5 years. [1] Two main categories of lung cancer have been defined: non-small-cell lung cancer (NSCLC) and small cell lung cancer (SCLC).